CA-EVIDATION
16.11.2023 15:01:58 CET | Business Wire | Press release
Evidation — the company creating new ways to measure and improve health in everyday life — today announced a landmark partnership with Our Future Health, a national health research initiative and collaboration between the UK’s National Health Service (NHS), public health agencies, non-profits, and leading life sciences companies. Our Future Health will deploy Evidation’s enterprise digital health engagement and measurement platform to conduct a multi-year, longitudinal research program for up to five million participants across the UK.
“Evidation and Our Future Health believe that deeply understanding individuals' everyday health experiences can accelerate discoveries that will transform health," said Christine Lemke, Co-founder and CEO of Evidation. "Together, with the participation of millions of volunteers across the UK, we will enable research that can advance more inclusive and effective ways to prevent, detect, and treat disease."
“Our Future Health aims to be a world-leading resource for health research,” said Dr Raghib Ali OBE, Chief Executive of Our Future Health. “Evidation has extensive expertise measuring and characterizing health in everyday life and engaging people at scale. This, combined with their experience in deploying large research and engagement programs and their shared commitment to the highest standards of data protection and user privacy, makes them the ideal partner for Our Future Health.”
Our Future Health is bringing together up to five million people to develop new ways to prevent, detect and treat diseases. To achieve this, Our Future Health will recruit a diverse and inclusive cohort of people across the UK who have consented to participate. The program population accounts for almost 10% of the UK’s adult population of over 53 million people. Evidation’s technology will power the digital experience, including a participant-facing app and technology infrastructure, that makes this massive research initiative possible. This new digital experience will be developed in the coming months.
Evidation’s platform is the technology layer that powers health research and engagement programs for some of the world’s leading healthcare organizations. Evidation makes it possible to harness real-world data — including wearables and survey data — to deeply understand health experiences rapidly and longitudinally, in large populations. Refined over a decade, Evidation’s measurement and engagement platform helps capture health data from outside the clinic and rewards participants for taking healthy actions.
About Evidation
Evidation creates new ways to measure and improve health in everyday life — making proactive, personalized, and truly human-centered healthcare possible. By connecting directly with millions of individuals, Evidation harnesses real-world data to deeply understand health experiences, rapidly and at scale. Evidation’s privacy-centric digital health measurement and engagement platform uses data science and machine learning to translate these everyday insights into high-impact health guidance, treatments, and tools. Founded in 2012, Evidation is headquartered in California with employees working around the globe. Learn more at www.evidation.com.
About Our Future Health
Our Future Health is a collaboration between the public, private and charity sectors. It aims to be the UK’s largest health research program, bringing people together to develop new ways to prevent, detect and treat disease.
Our Future Health is committed to the highest standards, policies and processes that protect participants’ confidentiality, whilst maximizing the opportunity to help researchers to tackle serious diseases. Participants’ data is de-identified and held securely in trusted research environments that meet strict security criteria. There is a robust and transparent access process to ensure appropriate research access to Our Future Health data and samples for registered researchers. All researchers are held to the same standards.
Our Future Health is a member of the UK Health Data Research Alliance, the independent alliance of leading healthcare and research organizations establishing best practice for the ethical use of UK health data for research at scale.
Our Future Health is a company limited by guarantee registered in England and Wales (number 12212468) and a charity registered with the Charity Commission for England and Wales (charity number 1189681) and OSCR, Scottish Charity Regulator (charity number SC050917).
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20231116712663/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Three Weeks into France E-Invoicing Mandate: Sovos Hits Unparalleled Production Scale23.9.2026 10:00:00 CEST | Press release
With 170,000 registrants - 78x the registered network reach of the nearest tax compliance competitor - Sovos demonstrates unmatched production scale across direct clients and every software platform embedding its Compliance Network Sovos, the agentic tax compliance company, today announced that it has surpassed 170,000 organizations registrants across the Sovos-powered network – including both Sovos-branded and partner-branded approved service providers - using Sovos technology in France. By comparison, the nearest competitors registered fewer than 2,200 organizations each. The milestone represents a significant lead in production-grade e-invoicing, with Sovos handling transaction volumes that are many multiples higher than any other tax compliance vendor operating in France. "France represents the most complex continuous transaction controls mandate the world has seen, and we entered production on day one with our Global 2000 clients fully live," said Kevin Akeroyd, CEO, Sovos. "We ac
Thredd Partners with Velocity to Expand Global Payments Platform, Offer Stablecoin-Powered Money Movement23.9.2026 09:00:00 CEST | Press release
New capabilities will connect cards, fiat payment rails, and stablecoins through one integrated platform experience Thredd, the AI-first issuer processing platform, today announced the expansion of its payments platform to include stablecoin-powered money movement capabilities, through a partnership with Velocity, the stablecoin treasury and settlement platform bringing enterprises onchain. The initial rollout of these capabilities will focus on supporting B2B and B2B2B applications, including stablecoin-backed card programmes, cross-border payouts, global treasury flows and on-chain settlement. Thredd clients will now be able to convert between fiat currencies and supported stablecoins, send funds on-chain or through connected fiat rails, and use stablecoins for funding, payouts and settlement. “Stablecoins are rapidly becoming an important part of global payments infrastructure, but clients should not have to rebuild their payments stack to take advantage of them,” said Jim McCarthy,
Mentimeter Launches Three New Tools for Better Leadership23.9.2026 09:00:00 CEST | Press release
Mentimeter is launching an engagement suite with three new tools: Menti Live, Menti Form and Menti Pulse. Through interaction, insights and recommendations, the new suite enables organizations to engage people live, collect input asynchronously and track important signals over time. Today’s launch expands Mentimeter’s platform beyond live presentations, helping turn participation into new ways of understanding what people think, know and need. “Most organizations have plenty of data, but surprisingly little understanding of what their people actually think. These new tools give leaders a way to turn participation into company-wide performance – in the room, afterward and over time. That creates better input for action and, ultimately, better leadership,” says Johnny Warström, CEO and founder of Mentimeter. Three tools for different moments of engagement Menti Form collects input asynchronously. It allows for shared reflection and gives people the opportunity to contribute regardless of
EADV 2026: Galderma to Unveil New Data Advancing Understanding of Skin Diseases, Skin Longevity, and Real-world Patient Experiences23.9.2026 07:00:00 CEST | Press release
Galderma will present 19 abstracts, including two oral presentations, at the 2026 EADV Congress, with new data on skin diseases, skin longevity and real-world patient experiences New analyses from the Nemluvio® (nemolizumab) clinical development program will explore long-term data, in line with Galderma’s commitment to improving the outcomes that matter most to patients1-7 Galderma will also present new research on sensitive skin, dermatoporosis, and acne, evaluating more personalized management approaches and the role of skincare in maintaining barrier function, skin resilience, and longevity8-19 The company will also host educational activities, including a symposium on atopic dermatitis and prurigo nodularis, an Industry Expert Hub session on targeting cellular senescence for skin longevity, a Cetaphil® Innovation Forum and Meet-the-Expert sessions and masterclasses Together, these presentations reflect Galderma's commitment to advancing scientific understanding, helping to shape th
Oticon Medical Launches SmartCharger for the Ponto 5 Family23.9.2026 07:00:00 CEST | Press release
Oticon Medical’s first rechargeable solution for Ponto sound processors Oticon Medical today announces the launch of SmartCharger for the Ponto 5 family, introducing its first rechargeable solution for percutaneous sound processors and marking a new step in convenience and portability for bone anchored hearing system users. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260922863462/en/ Oticon Medical today announces the launch of SmartCharger for the Ponto 5 family, introducing its first rechargeable solution for percutaneous sound processors and marking a new step in convenience and portability for bone anchored hearing system users. Powering the Ponto 5 family The launch of SmartCharger underlines Oticon Medical’s continued commitment to the Ponto family, which includes Ponto 5 SuperPower, the world’s most powerful abutment-level sound processor,1 and Ponto 5 Mini, the world’s smallest percutaneous sound processor.1 By br
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
